https://www.selleckchem.com/pr....oducts/pnd-1186-vs-4
001] blood transfusions were at greater risk for 30-day readmission. Median follow-up period was 4.19 years (2.45 - 6.1. The 30-day readmission cohort had a significantly higher mortality risk during early (6 months) follow-up [HR 2.49 (2.01-3.1; P less then 0.001] and late (60 months) follow-up [HR 1.30 (1.16-1.47); P less then 0.001]. After risk adjustment, the 30-day readmission cohort was significantly associated with increased mortality over the study follow-up period [HR 1.62 (1.48, 1.78); P less then 0.001]. 30-day r
Like
Comment
Share
